New stem cell filter could make transplants safer for vulnerable patients
NCT ID NCT06731036
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program offers a special stem cell purification technique (CD34+ selection) for patients undergoing stem cell transplants. The method removes many T-cells from the donated stem cells, which lowers the risk of a serious complication called graft-versus-host disease. It is available for patients with severe combined immunodeficiency, Fanconi anemia, dyskeratosis congenita, or sickle cell disease who need a transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD34+ cell enriched stem cell graft
- What this could lead to
- If successful, this could provide a safer stem cell transplant option for patients with severe immune deficiencies or sickle cell disease by reducing the risk of graft-versus-host disease.
- What could go wrong
- This is an expanded access program, not a formal trial, so results are not systematically collected. The procedure still carries risks like infection or graft failure, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSKERATOSIS CONGENITA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease